Percutaneous or Endoscopic Gallbladder Drainage: The PEG Trial

Clinical Trial Information

Trial Phone: 321-841-7246

Principal Investigator: Ji Bang, MD

Phase: N/A

Age Group:

ClinicalTrials.gov ID: NCT99999999

Objective

The primary outcome is a combination of three events tracked from the initial procedure through 36 months after. These events include complications from the procedure, the need for another procedure due to disease return or complications, and hospital readmission for the disease or procedure-related issues. This combined measure is used to evaluate patient outcomes over the follow-up period.

Share:

Related Clinical Trials

Bleximenib or Placebo in Combination with Standard Induction and Consolidation Therapy Followed by Maintenance for the Treatment of Patients with Newly Diagnosed KMT2A-Rearranged or NPM1-Mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy: A Double-Blind Phase III Study
A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)
An Interventional Phase Ib/II Study to Evaluate the Safety and Efficacy of PF-08634404 Monotherapy and in Combination with Other Anticancer Agents in Adult Participants with Locally Advanced or Metastatic Renal Cell Carcinoma
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, PARALLEL GROUP, MULTICENTER STUDY WITH OPEN-LABEL EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF FENFLURAMINE HYDROCHLORIDE IN STUDY PARTICIPANTS WITH RETT SYNDROME